Brokerages Set GoodRx Holdings, Inc. (NASDAQ:GDRX) PT at $8.18

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $8.18.

Several equities research analysts have commented on the stock. Citigroup dropped their price target on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research report on Friday, January 10th. Mizuho initiated coverage on shares of GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price for the company. Morgan Stanley decreased their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Wells Fargo & Company cut their price objective on GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Finally, KeyCorp reduced their price objective on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th.

GoodRx Stock Down 4.1 %

GDRX opened at $4.47 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The company has a market capitalization of $1.71 billion, a PE ratio of -149.00, a P/E/G ratio of 2.46 and a beta of 1.25. The stock’s fifty day moving average is $4.72 and its 200-day moving average is $5.58. GoodRx has a one year low of $4.09 and a one year high of $9.26.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. CWA Asset Management Group LLC purchased a new position in shares of GoodRx during the 3rd quarter valued at $370,000. Quest Partners LLC acquired a new stake in GoodRx during the third quarter valued at $160,000. Charles Schwab Investment Management Inc. grew its stake in GoodRx by 5.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock valued at $3,332,000 after purchasing an additional 26,262 shares in the last quarter. Dynamic Technology Lab Private Ltd increased its position in GoodRx by 260.7% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock worth $308,000 after purchasing an additional 32,104 shares during the last quarter. Finally, Rubric Capital Management LP lifted its holdings in shares of GoodRx by 25.2% during the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after buying an additional 943,226 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.